Last reviewed · How we verify
oxygenotherapy
At a glance
| Generic name | oxygenotherapy |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-invasive Ventilation Following Extubation (Prophylactic) to Prevent Extubation Failure in Critically Obese Patients (NA)
- Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx) (PHASE4)
- Diaphragmatic Work During HFNC and CPAP Support (NA)
- Evaluation of Sores Treatment by Oxygenotherapy (NA)
- Efficacy of Oxygen Therapy Delivered by Systems Using Oxygen-Saving Valves in COPD Patients (NA)
- PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study) (NA)
- Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)
- Non Invasive Evaluation of Muscle Hypoxia in COPD Patient (EVANIMUS) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxygenotherapy CI brief — competitive landscape report
- oxygenotherapy updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI